IMPACT OF INFECTION BY H. PYLORI ON GASTRIC PARIETAL CELL PHYSIOLOGY: REVIEW

Noor Zuhair Bakheet NZ

doi:10.61796/jmgcb.v2i10.1407

Authors

Noor Zuhair Bakheet NZ
noor.z.bakheet@jmu.edu.iq
Jabir Ibn Hayyan University for Medical & Pharmaceutical Science, Iraq

Vol. 2 No. 10 (2025): Journal of Medical Genetics and Clinical Biology

Articles

August 18, 2025

Downloads

VIEW ARTICLE

Abstract
How to Cite
Metrics
References
License

Objective: This review aims to highlight the strategies used by Helicobacter pylori to influence the physiology of gastric parietal cells, affecting gastric acid secretion, epithelial elasticity, and the development of various gastric diseases. Method: The study reviews existing literature on Helicobacter pylori infection and its impact on gastric parietal cells, including mechanisms of colonization, inflammatory response, and physiological effects on the stomach and duodenum. Results: Helicobacter pylori infection can significantly affect parietal cells, which are essential for gastric acid production. Upon Helicobacter pylori infection, inflammatory cells replace normal glandular cells, leading to hypo- or hyperchloremia, based on the colonization site in the stomach. Chronic colonization of the gastric lumen promotes hyperacidity and duodenal ulcers, while hypoacidity resulting from long-term Helicobacter pylori infection of the gastric corpuscle and fundus increases the risk of gastric cancer and may damage these cells, gastric atrophy, and other complications. Novelty: In summary, Helicobacter pylori infection has a complex and multifaceted effect on the physiology of gastric parietal cells, affecting acid secretion, epithelial cell elasticity, and the development of various gastric diseases.

C. D. Varela and N. Segura, “Histology, parietal cells,” StatPearls [Internet]. StatPearls Publishing, May 1, 2023.

M. Hsu, A. O. Safadi, and F. Lui, “Physiology, stomach,” StatPearls [Internet]. StatPearls Publishing, Jul. 17, 2023.

A. C. Engevik, I. Kaji, and J. R. Goldenring, “The physiology of the gastric parietal cell,” Physiol. Rev., vol. 100, no. 2, pp. 573–602, 2020.

P. N. Rathore, S. Gupta, R. Madhariya, and A. Ram, “Vitamin B12 malabsorption: The pathophysiological impacts on neurological and hair physiology,” Int. J. Gastroenterol. Hepatol. Dis., vol. 4, no. 1, p. E26662906322948, Jan. 2025.

R. Heda, F. Toro, and C. R. Tombazzi, “Physiology, pepsin,” StatPearls [Internet]. StatPearls Publishing, May 1, 2023.

H. P. Festen, “Intrinsic factor secretion and cobalamin absorption: physiology and pathophysiology in the gastrointestinal tract,” Scand. J. Gastroenterol., vol. 26, sup188, pp. 1–7, 1991.

M. L. Schubert and J. F. Rehfeld, “Gastric peptides—gastrin and somatostatin,” Compr. Physiol., vol. 10, no. 1, pp. 197–228, Jan. 2020.

J. H. Walsh, “Role of gastrin as a trophic hormone,” Digestion, vol. 47, Suppl. 1, pp. 11–16, 1990.

M. L. Schubert, “Hormonal regulation of gastric acid secretion,” Curr. Gastroenterol. Rep., vol. 10, pp. 523–527, 2008.

G. Cui and H. L. Waldum, “Physiological and clinical significance of enterochromaffin-like cell activation in the regulation of gastric acid secretion,” World J. Gastroenterol., vol. 13, pp. 493–496, 2007.

Y. Y. Cheok et al., “An overview of Helicobacter pylori survival tactics in the hostile human stomach environment,” Microorganisms, vol. 9, no. 12, p. 2502, Dec. 2021.

R. M. Peek and J. E. Crabtree, “Helicobacter infection and gastric neoplasia,” J. Pathol., vol. 208, pp. 233–248, 2006.

V. E. Reyes, “Helicobacter pylori and its role in gastric cancer,” Microorganisms, vol. 11, no. 5, p. 1312, May 2023.

A. Elbehiry et al., “Helicobacter pylori infection: current status and future prospects on diagnostic, therapeutic and control challenges,” Antibiotics, vol. 12, no. 2, p. 191, Jan. 2023.

O. S. Joy, E. F. Aluko, O. R. Ayanbolade, and O. A. Olowe, “Public health perspectives of zoonotic potential of H. pylori,” Adv. Anal. Pathol., vol. 1, pp. 22–38, 2025.

E. A. Marcus and D. R. Scott, “Gastric colonization by H. pylori,” in Helicobacter pylori. Singapore: Springer Nature Singapore, 2024, pp. 25–37.

L. E. Wroblewski and R. M. Peek, “Targeted disruption of the epithelial-barrier by Helicobacter pylori,” Cell Commun. Signal., vol. 9, p. 29, 2011.

Z. Hua et al., “Helicobacter pylori infection altered gastric microbiota in patients with chronic gastritis,” Front. Cell. Infect. Microbiol., vol. 13, p. 1221433, Aug. 2023.

L. Zhang, X. Chen, B. Ren, X. Zhou, and L. Cheng, “Helicobacter pylori in the oral cavity: current evidence and potential survival strategies,” Int. J. Mol. Sci., vol. 23, no. 21, p. 13646, Nov. 2022.

D. K. Sah, A. Arjunan, B. Lee, and Y. D. Jung, “Reactive oxygen species and H. pylori infection: a comprehensive review of their roles in gastric cancer development,” Antioxidants, vol. 12, no. 9, p. 1712, Sep. 2023.

H. H. Xia and N. J. Talley, “Apoptosis in gastric epithelium induced by Helicobacter pylori infection: implications in gastric carcinogenesis,” Am. J. Gastroenterol., vol. 96, pp. 16–26, 2001.

S. K. Bashir and M. B. Khan, “Overview of Helicobacter pylori infection, prevalence, risk factors, and its prevention,” Adv. Gut Microbiome Res., vol. 2023, no. 1, p. 9747027, 2023.

R. M. Genta, “Helicobacter pylori, inflammation, mucosal damage, and apoptosis: pathogenesis and definition of gastric atrophy,” Gastroenterology, vol. 113, no. 6 Suppl., pp. S51–S55, 1997.

A. Lee et al., “Local acid production and Helicobacter pylori: a unifying hypothesis of gastroduodenal disease,” Eur. J. Gastroenterol. Hepatol., vol. 7, pp. 461–465, 1995.

H. Patel, A. Kwamboka, D. Magembe, E. Manyinsa, and K. Ouma, “Valuation of prescription patterns of Helicobacter pylori drugs in outpatient department, Meru Teaching and Referral Hospital,” Afr. J. Health Sci., vol. 36, no. 6, pp. 733–738, 2023.

X. Yao and A. J. Smolka, “Gastric parietal cell physiology and Helicobacter pylori–induced disease,” Gastroenterology, vol. 156, no. 8, pp. 2158–2173, Jun. 2019.

M. A. Ferraz et al., “Downregulated expression of e-cadherin and tp53 in patients with gastric diseases: the involvement of H. pylori infection and its virulence markers,” J. Gastrointest. Cancer, vol. 47, no. 1, pp. 20–26, Mar. 2016.

Y. K. Wang et al., “How does Helicobacter pylori infection cause gastric mucosal atrophy,” Infect. Drug Hesist., vol. 15, pp. 3619–3629, Jan. 2022.

H. Aslam, A. U. Khan, N. G. Qazi, F. Ali, S. S. Hassan, and S. Bungau, “Pharmacological basis of bergapten in gastrointestinal diseases focusing on H+/K+ ATPase and voltage-gated calcium channel inhibition: A toxicological evaluation on vital organs,” Front. Pharmacol., vol. 13, p. 1005154, Nov. 2022.

Y. K. Wang et al., “Histopathological features of Helicobacter pylori infection in gastric mucosa,” J. Inflamm. Res., vol. 15, pp. 6231–6243, Jan. 2022.

R. Veysey-Smith et al., “Effects of proton pump inhibitor therapy, H. pylori infection and gastric preneoplastic pathology on fasting serum gastrin concentrations,” Front. Endocrinol., vol. 12, p. 741887, Nov. 2021.

J. Geibel, “Gastric secretions,” in Yamada's Textbook of Gastroenterology. Hoboken, NJ: Wiley, Apr. 2022, pp. 313–333.

A. Minalyan, L. Gabrielyan, D. Scott, J. Jacobs, and J. R. Pisegna, “The gastric and intestinal microbiome: role of proton pump inhibitors,” Curr. Gastroenterol. Rep., vol. 19, no. 8, p. 42, Aug. 2017.

Y. Huang, Q. L. Wang, D. D. Cheng, W. T. Xu, and N. H. Lu, “Adhesion and invasion of gastric mucosa epithelial cells by Helicobacter pylori,” Front. Cell. Infect. Microbiol., vol. 6, p. 159, Nov. 2016.

S. K. Motupalli and T. L. Oroszi, “The nexus between Helicobacter pylori infection and anemia—a systematic review,” Front. Hematol., vol. 3, p. 1423494, Aug. 2024.

H. Aljaberi et al., “Current understanding of the transmission, diagnosis, and treatment of H. pylori infection: A comprehensive review,” Int. J. Med. Pharm. Drug Res., vol. 7, p. 2, 2023.

V. V. Lupu et al., “Iron deficiency anemia in pediatric gastroesophageal reflux disease,” Diagnostics, vol. 13, no. 1, p. 63, Dec. 2022.